Serum neurofilament light chain and disease-modifying treatment as predictors of cognitive decline in multiple sclerosis
Our findings highlight the potential of serum NfL as a marker of early IPS decline. Treatment with higher-efficacy DMTs early after diagnosis may be protective against early cognitive decline in MS.
Authors
- Gintaras Kaubrys (ORCID: https://orcid.org/0000-0003-4998-8403)
- Rasa Kizlaitienė (ORCID: https://orcid.org/0000-0002-0493-9686)
- Vera Taluntienė
- Mantas Vaišvilas (ORCID: https://orcid.org/0000-0002-9306-610X)
- Nataša Giedraitienė (ORCID: https://orcid.org/0000-0003-2111-363X)
Institutions
- Vilnius University (LT)
Publication Details
- Journal
- Frontiers in Neurology
- Published
- 2026-02-04
- DOI
- https://doi.org/10.3389/fneur.2026.1743472
- Primary Topic
- Multiple Sclerosis Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00